POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE

被引：0
|
作者：
Gomez, Hernando Marta [1 ]
Gironella, Merce [2 ]
Abella, Eugenia [3 ]
Cabezudo, Elena [4 ]
Motllo, Cristina [5 ]
Garcia, Antoni [6 ]
Sarra, Josep [7 ]
Mostacedo, Silvia [8 ]
Granell, Miquel [9 ]
Rosinol, Laura [1 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Hosp Valle De Hebron, Barcelona, Spain
[3] Hosp Mar, Barcelona, Spain
[4] Hosp Moises Broggi ICO Hosp, Barcelona, Spain
[5] Fundacio Althaia, Barcelona, Spain
[6] Hosp Arnau Vilanova, Lledia, Spain
[7] Hosp Joan 23, Tarragona, Spain
[8] Hosp Josep Trueta, Girona, Spain
[9] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO-011
引用
收藏
页码：13 / 14
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen.
    Berenson, James R.
    Cohen, Alexa
    Spektor, Tanya M.
    Lashkari, Ashkan
    Mackintosh, Roy
    Bessudo, Alberto
    Robinson, Michael Oren
    Jhangiani, Haresh S.
    Gabrail, Nashat Y.
    Nakhoul, Ibrahim
    Kubba, Samir V.
    Neidhart, Jeffrey D.
    Maluso, Tina
    Swift, Regina A.
    Vescio, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma
    Sheridan M. Hoy
    [J]. Drugs, 2017, 77 : 1897 - 1908
  • [43] A meta-analysis of efficacy of pomalidomide-based regimens for the treatment of relapsed or refractory multiple myeloma (RRMM) after lenalidomide (LEN) exposure
    Weisel, Katja
    Davies, Faith E.
    Leleu, Xavier
    Vogel, Prisca
    Dhanasiri, Sujith
    Le Nouveau, Pauline
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 172 - 173
  • [44] A phase I/II study of Pomalidomide, Ixazomib, Clarithromycin and Dexamethasone (PICd) in patients with relapsed or refractory Multiple Myeloma (RRMM)
    Rosenberg, Aaron
    Munoz, Meilen
    Costello, Caitlin
    Brem, Elizabeth
    Reid, Erin
    Maverakis, Emanual
    Kaesberg, Paul
    Lee, Lisa
    Abedi, Mehrdad
    Tuscano, Joseph
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S157 - S158
  • [45] Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone
    Shin, Junghoon
    Lee, Je-Jung
    Kim, Kihyun
    Min, Chang-Ki
    Lee, Jeong-Ok
    Suh, Cheolwon
    Kim, Jin Seok
    Lee, Yoo Jin
    Yoon, Sung-Soo
    Jo, Jae-Cheol
    Lee, Ho Sup
    Bang, Soo-Mee
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Lee, Je-Jung
    Kim, Kihyun
    Min, Chang-Ki
    Suh, Cheolwon
    Yoon, Dok Hyun
    Kim, Jin Seok
    Lee, Yoo Jin
    Moon, Joon Ho
    Yoon, Sung-Soo
    Kim, Inho
    Jo, Jae-Cheol
    Lee, Ho Sup
    Park, Seong Kyu
    Shin, Ho-Jin
    Kim, Min Kyoung
    Mun, Yeung-Chul
    Lee, Mark Hong
    Park, Yong
    Eom, Hyeon Seok
    Kim, Hyo Jung
    Im, Sung Nam
    Kim, Sung-Hyun
    Do, Young Rok
    Lee, Won Sik
    Cho, Su-Hee
    Yi, Jun Ho
    Lee, Jae Hoon
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 79 - 90
  • [46] Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone
    Junghoon Shin
    Je-Jung Lee
    Kihyun Kim
    Chang-Ki Min
    Jeong-Ok Lee
    Cheolwon Suh
    Jin Seok Kim
    Yoo Jin Lee
    Sung-Soo Yoon
    Jae-Cheol Jo
    Ho Sup Lee
    Soo-Mee Bang
    [J]. International Journal of Hematology, 2019, 109 : 79 - 90
  • [47] A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
    Dimopoulos, Meletios A.
    Richardson, Paul G.
    Brandenburg, Nancy
    Yu, Zhinuan
    Weber, Donna M.
    Niesvizky, Ruben
    Morgan, Gareth J.
    [J]. BLOOD, 2012, 119 (12) : 2764 - 2767
  • [48] Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment
    Matsue, Kosei
    Sunami, Kazutaka
    Matsumoto, Morio
    Kuroda, Junya
    Sugiura, Isamu
    Iwasaki, Hiromi
    Chung, Weiyuan
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Lee, Kim
    Iida, Shinsuke
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (01) : 122 - 130
  • [49] a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Berenson, James
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Regina, Swift A.
    James, Wang
    Benjamin, Eades
    Spektor, Tanya M.
    Vescio, Robert
    [J]. BLOOD, 2015, 126 (23)
  • [50] Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials.
    Paul, Barry
    Robinson, Myra M.
    Robinson, Jordan
    Ndiaye, Ami
    Bhutani, Manisha
    Voorhees, Peter Michael
    Symanowski, James Thomas
    Friend, Reed N.
    Pineda-Roman, Mauricio
    Usmani, Saad Zafar
    Atrash, Shebli
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345